deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT02141282

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Sponsor: AbbVie

Conditions Chronic Lymphocytic Leukemia
Interventions Venetoclax
Updated 19 times since 2017 Last updated: Nov 18, 2022 Started: Sep 10, 2014 Primary completion: Dec 22, 2021 Completion: Dec 22, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02141282, this PHASE2 trial focuses on Chronic Lymphocytic Leukemia and remains completed. Sponsored by AbbVie, it has been updated 19 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Feb 2018 · 7 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Dec 2018 · 4 months · monthly snapshot~Dec 2018 – ~Jul 2019 · 7 months · monthly snapshot~Jul 2019 – ~Dec 2019 · 5 months · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Jan 2023 · 11 months · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Feb 2022 — Jan 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 14 earlier versions

  1. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Jul 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Dec 2018 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Aug 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Feb 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  12. Jul 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE2

  13. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
  • Roche-Genentech
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Boston, United States , Chicago, United States , Columbus, United States , Houston, United States , La Jolla, United States , Los Angeles, United States , New York, United States , Philadelphia, United States , Rochester, United States and 3 more locations